// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Early experience with JAK inhibitor prescribing in the UK: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA)

Lianne Kearsley-Fleet - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Has modern UK management of RA led to a reduction in use of steroids and NSAIDs? 20-year data from the clinical practice research datalink

Samantha S. R Crossfield - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Methotrexate response clusters in JIA

Stephanie J. W Shoop-Worrall - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methotrexate

Long non-coding RNA HOTAIR induces beta catenin expression in systemic sclerosis through EZH2 dependent repression of Axin-2

Christopher W Wasson - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

GSK126

IL-27 regulates the magnitude of ectopic germinal centres in experimental sialadenitis but fails to modulate IL-17 and IFNg production in CD4 T cells from patients with Sjögren's syndrome

Davide Lucchesi - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Digital artery volume index (DAVIX©) predicts the onset of future digital ulcers in patients with SSc

Klodian Gjeloshi - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Earlier cancer diagnosis after myositis onset is associated with improved long term survival: results from UK, French and Czech cohorts

Alexander Oldroyd - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Juvenile dermatomyositis

N/A

Predicting autoimmune connective tissue diseases: three year follow up of an at-risk cohort identifies late progression and predicts need for therapy

Sabih Ul-Hassan - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Efficacy & safety of tocilizumab in GCA: a multi-centre experience of NHS clinical practice

Alwin Sebastian - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Tocilizumab

Validation of methods to enable national registration for rare autoimmune rheumatic diseases

Fiona A Pearce - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Eosinophilic granulomatosis with polyangiitis

N/A

Utility of RA classification criteria in early inflammatory arthritis referral prioritisation

Syed M Imaduddin - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Early inflammatory arthritis

N/A

The relationship between obesity and outcomes in patients with polymyalgia rheumatica

Ian C Scott - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Giant cell arteritis

Prednisolone

VTE risk in the general population: applying context to the impact of JAK inhibition

Serena Baroncini - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Trends in incidence of GCA in the UK

Lauren A Barnett - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Percentage body fat as a predictor for fragility fracture: an observational study

Dominic T Beith - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Hydroxychloroquine retinopathy: is screening necessary?

Anne Gobbett - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic retinopathy

Hydroxychloroquine

Osteoporosis management when denosumab therapy ends: an audit of current practice

Jean Zhang - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoporosis

Denosumab

Effectiveness and tolerability of Benepali in patients switched from Enbrel with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthropathy

Brandon Yeo - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Etanercept biosimilar

Involving patients in the discussion about results from the National Early Inflammatory Arthritis Audit

Oliver Wade - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Early inflammatory arthritis

N/A

Driving up quality: local observations from the National Early Inflammatory Arthritis Audit

Jack Loh - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Early inflammatory arthritis

N/A

Copyright © 2026. QuantiNova All rights reserved